

# JPMorgan Funds -

# **Europe Strategic Value Fund**

Class: JPM Europe Strategic Value D (acc) - EUR

## **Fund overview**

|   | ISINBloombergLU0117858752FLEESVC LX                                |  | Reuters<br>LU0117858752.LUF |  |
|---|--|--|-----------------------------|--|
| Investment objective: To provide long-term capital growth by investin |  |  |                             |  |
|   | primarily in a value style-biased portfolio of European companies. |  |                             |  |

## Investment approach

- Uses a bottom-up stock selection process.
- Uses the full breadth of the eligible equity investment universe through a combination of fundamental research insights and quantitative analysis.
- Seeks to identify attractively valued companies that are fundamentally sound.

| Portfolio manager(s) | Share class   | Class launch             |
|----------------------|---------------|--------------------------|
| Michael Barakos      | currency EUR  | 13 Oct 2000              |
| lan Butler           | Fund assets   | Domicile Luxembourg      |
| Thomas Buckingham    | EUR 1493.5m   | Entry/exit charges       |
| Fund reference       | Fund launch   | Entry charge (max) 5.00% |
| currency EUR         | 14 Feb 2000   | Exit charge (max) 0.50%  |
|                      | NAV EUR 22.73 | Ongoing charge 2.51%     |
|                      |               |                          |

## ESG information

ESG approach - ESG Promote

Promotes environmental and / or social characteristics.

## SFDR classification: Article 8

"Article 8" strategies promote social and/or environmental characteristics, but do not have sustainable investing as a core objective.

## Fund ratings As at 31 October 2024

Morningstar Category™ Europe Large-Cap Value Equity

## Performance

1 Class: JPM Europe Strategic Value D (acc) - EUR 2 Benchmark: MSCI Europe Value Index (Total Return Net)

Growth of EUR 100,000 Calendar years



|   | Cumulative |          |        | A     | Annualised |         |          |
|---|------------|----------|--------|-------|------------|---------|----------|
|   | 1 month    | 3 months | 1 year | YTD   | 3 years    | 5 years | 10 years |
| 1 | -2.15      | -1.86    | 19.38  | 10.55 | 6.68       | 5.71    | 4.50     |
| 2 | -1.99      | -0.38    | 20.23  | 10.41 | 8.91       | 6.97    | 5.22     |

## Performance Disclosures

Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested.

### ESG

For more information on our approach to sustainable investing at J.P. Morgan Asset Management please visit https://am.jpmorgan.com/lu/esg



# Portfolio analysis

| Measurement               | 3 years 5 year |       |
|---------------------------|----------------|-------|
| Correlation               | 0.97           | 0.98  |
| Alpha (%)                 | -2.04          | -1.18 |
| Beta                      | 1.06           | 1.15  |
| Annualised volatility (%) | 14.65          | 21.03 |
| Sharpe ratio              | 0.38           | 0.33  |
| Tracking error (%)        | 3.49           | 4.82  |
| Information ratio         | -0.54          | -0.11 |

# Holdings

| Roche Bio<br>Sc<br>Novartis Bio | narmaceuticals<br>otechnology & Life<br>si<br>narmaceuticals | 4.1 |
|---------------------------------|--|-----|
| Novartis Bio                    | harmaceuticals   |     |
| Sc                              | otechnology & Life   | 4.0 |
| Shell En                        | nergy  | 3.9 |
| HSBC Ba                         | anks   | 3.3 |
| TotalEnergies En                | nergy  | 2.4 |
| Allianz Ins                     | surance  | 2.3 |
|                                 | narmaceuticals<br>otechnology & Life<br>ci                   | 2.2 |
| Deutsche Lelekom                | elecommunication<br>ervices                                  | 2.0 |
| Zurich Insurance Ins            | surance  | 1.6 |
| Banco Santander Ba              | anks   | 1.5 |

| Regions (%)    |      | Compared to benchmark |
|----------------|------|-----------------------|
| United Kingdom | 26.3 | 0.0                   |
| Germany        | 14.2 | -1.6                  |
| France         | 13.6 | -2.0                  |
| Switzerland    | 12.6 | -2.8                  |
| Italy          | 7.4  | +1.8                  |
| Spain          | 4.4  | -1.3                  |
| Netherlands    | 4.0  | -0.8                  |
| Sweden         | 3.4  | -0.2                  |
| Norway         | 2.4  | +0.9                  |
| Finland        | 2.1  | -0.6                  |
| Others         | 5.6  | +2.6                  |
| Cash           | 4.0  | +4.0                  |

| Sectors (%)                                 | Compared to benchmark |      |  |
|---|-----------------------|------|--|
| Banks                                       | 22.4                  | +5.2 |  |
| Insurance                                   | 13.1                  | +2.8 |  |
| Pharmaceuticals Biotechnology<br>& Life Sci | 10.8                  | -0.2 |  |
| Energy                                      | 10.3                  | +0.9 |  |
| Capital Goods                               | 5.5                   | -2.7 |  |
| Utilities                                   | 4.9                   | -3.0 |  |
| Telecommunication Services                  | 4.8                   | +0.5 |  |
| Financial Services                          | 4.2                   | +1.6 |  |
| Materials                                   | 3.9                   | -3.2 |  |
| Automobiles & Components                    | 2.7                   | -0.2 |  |
| Others                                      | 13.4                  | -5.7 |  |
| Cash  | 4.0                   | +4.0 |  |

# Market cap (%) (USD)





## Key risks

The Sub-Fund is subject to **Investment risks** and **Other associated risks** from the techniques and securities it uses to seek to achieve its objective. The table on the right explains how these risks relate to each other and the **Outcomes to the Shareholder** that could

affect an investment in the Sub-Fund. Investors should also read <u>Risk Descriptions</u> in the Prospectus for a full description of each risk.

Market

Investment risks Risks from the Sub-Fund's techniques and securities

| <b>Techniques</b><br>Hedging<br>Style bias | <i>Securities</i><br>Equities |
|--|-------------------------------|
|  |                               |

Other associated risks Further risks the Sub-Fund is exposed to from its use of the techniques and securities above

Currency

Outcomes to the Shareholder Potential impact of the risks above

| outcomes to the shareholder rotential impact of the hsrs abo |                     |                     |            |
|--|---------------------|---------------------|------------|
| Loss Volatility  |                     | Failure to meet the |            |
|  | Shareholders        | Shares of the Sub-  | Sub-Fund's |
|  | could lose some or  | Fund will fluctuate | objective. |
|  | all of their money. | in value.           |            |

#### **General Disclosures**

Before investing, obtain and review the current prospectus, Key Information Document (KID) and any applicable local offering document. These documents, as well as the sustainability-related disclosures, the annual and semi-annual reports and the articles of incorporation, are available in English free from your financial adviser, your J.P. Morgan Asset Management regional contact, the fund's issuer (see below) or at <u>www.jpmam.lu</u>. A summary of investor rights is available in English at

<u>https://am.jpmorgan.com/lu/investor-rights</u>. J.P. Morgan Asset Management may decide to terminate the arrangements made for the marketing of its collective investment undertakings.

This material should not be considered as advice or an investment recommendation. Fund holdings and performance are likely to have changed since the report date.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy www.jpmorgan.com/emea-privacy-policy

For additional information on the sub-fund's target market please refer to the Prospectus.

Risk Indicator - The risk indicator assumes you keep the product for 5 year(s). The risk of the product may be significantly higher if held for less than the recommended holding period.

Current ongoing charge comprises annual management fee and operating & administrative expenses. Excludes transaction costs and may differ from ongoing costs as per KID which are an estimate based on the actual costs incurred over the past year.

### Performance information

Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees.

The return of your investment may change as a result of currency

fluctuations if your investment is made in a currency other than that used in the past performance calculation.

Indices do not include fees or operating expenses and you cannot invest in them.

The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.

## Holdings information

Market Cap excludes cash.

## Information Sources

Fund information, including performance calculations and other data, is provided by J.P. Morgan Asset Management (the marketing name for the asset management businesses of JPMorgan Chase & Co. and its affiliates worldwide).

All data is as at the document date unless indicated otherwise. © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

#### lssuer

JPMorgan Asset Management (Europe) S.à r.l., 6, route de Trèves, L-2633 Senningerberg, Luxembourg. B27900, corporate capital EUR 10.000.000.

## Definitions

**NAV** Net Asset Value of a fund's assets less its liabilities per Share. **Correlation** measures the strength and direction of the relationship between movements in fund and benchmark returns. A correlation of 1.00 indicates that fund and benchmark returns move in lockstep in the same direction.

Alpha (%) a measure of excess return generated by a manager compared to the benchmark. An alpha of 1.00 indicates that a fund has outperformed its benchmark by 1%.

Beta measures a fund's sensitivity to market movements (as represented by the fund's benchmark). A beta of 1.10 suggests the fund could perform 10% better than the benchmark in up markets and 10% worse in down markets, assuming all other factors remain constant. Usually the higher betas represent riskier investments. Annualised volatility (%) measures the extent to which returns vary up and down over a given period.

Sharpe ratio performance of an investment adjusting for the amount of risk taken (compared a risk-free investment). The higher the Sharpe ratio the better the returns compared to the risk taken. Tracking error (%) measures how much a fund's returns deviate from those of the benchmark. The lower the number the closer the fund's historic performance has followed its benchmark.

Information ratio measures if a manager is outperforming or underperforming the benchmark and accounts for the risk taken to achieve the returns. A manager who outperforms a benchmark by 2% p.a. will have a higher IR than a manager with the same outperformance but who takes more risk.